No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Aran Biomedical Teoranta Announces the Appointment of Todd Blair to the Newly Created Role of VP US Sales & Business Development

Editor: What To Know

  • Todd will be responsible for leading the Company’s sales and business development activities in the US marketplace with a primary focus on the Orthopaedic, General Surgery and Vascular fields.
  • “We welcome Todd to Aran Biomedical and are delighted to appoint a candidate of his calibre as Vice President of Sales and Business Development (US),”.
  • Todd brings more than 20 years of experience in sales and business development within the life sciences contract manufacturing industry, with a focus on implantable materials and technologies.

June 29, 2020

Aran Biomedical announced the appointment of Mr. Todd Blair as Vice President of Sales and Business Development (US), with effect 1st July 2020.

Aran Biomedical notes this role has been created to meet and manage the growing demand for the companies implantable biomaterial product solutions. Todd will be responsible for leading the Company’s sales and business development activities in the US marketplace with a primary focus on the Orthopaedic, General Surgery and Vascular fields.

Todd Blair joins the company from Heraeus Medical Components where he held the role of Vice President of Corporate Strategy. Todd brings more than 20 years of experience in sales and business development within the life sciences contract manufacturing industry, with a focus on implantable materials and technologies; including Bio-Textiles, Nitinol devices and polymeric components. Todd will support the companies growth plans by identifying new business opportunities and developing and growing those relationships into sustainable and long-term partnerships. In addition, Todd will support internal teams on proposal and product solution development.

“We welcome Todd to Aran Biomedical and are delighted to appoint a candidate of his calibre as Vice President of Sales and Business Development (US),” said Peter Mulrooney CEO, of the company. “The creation of this new position highlights the increasing level of interest Aran Biomedical is seeing in our implantable biomaterial products and services. It also demonstrates the importance of the US market to Aran Biomedical’s growth and expansion plans. We look forward to benefiting from Todd’s vast biomedical textile experience and contact network, to further expand our market presence, particularly for the Orthopaedics, Vascular and General Surgery fields, which are our key growth drivers.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy